

Industry
Liaison Forum



**STRATEGIC PLAN
2020 - 2023**



The **IAS Industry Liaison Forum** promotes and facilitates the full contribution of the biomedical industry to the global HIV response by catalyzing multi-stakeholder dialogue, engagement and action to address barriers along the HIV prevention, diagnosis and care continuum.

MEMBERSHIP

The ILF consists of members who come from a diversity of backgrounds, expertise and affiliations, both from industry and non-industry organizations.

Industry Members

- biopharmaceutical companies (originator and generic)
- diagnostics companies
- health-related product manufacturers (e.g., condom companies)
- other health-technology companies


Non-Industry Members

- the IAS
- regulatory and normative agencies
- procurement and implementing organizations
- governmental and inter-governmental organizations
- civil society and communities affected by HIV/AIDS



Appendix 1: Evolution of ILF Industry Members

HISTORY



THE ILF TODAY

A strategic review led by independent consultants in 2020 highlighted that, overall, **the ILF is appreciated by its members, who see it as unique due to its:**

- **focus on advancing the global HIV response**, particularly in low-income countries;
- **neutrality and convening power** – from its affiliation with the IAS;
- **composition** – which brings together a diversity of industry and non-industry stakeholders (spanning a range of backgrounds, expertise and affiliations) who seldom have a chance to meet and exchange openly;
- way of regarding, treating and **respecting ILF industry members as partners** (rather than ‘adversaries’) in the HIV response, and giving them a voice in shaping ILF priorities; and
- **rules of engagement** that simultaneously create a collegial, safe, constructive space for dialogue and engagement, and ensure compliance with ethical rules.

MOVING FORWARD


The strategic review concluded that:

- there is value in fostering connection and dialogue within the ILF membership;
- the ILF can usefully draw attention to HIV issues and possible solutions by making its perspectives known; and
- with the ILF's composition having broadened (in particular to include a wider variety of companies) and member interests having evolved over time, there is an appetite amongst members to refresh and reenergize the ILF.



Through this 2020-2023 Strategic Plan, the ILF wishes to further build on its unique attributes to revitalize its value to ILF members, and strengthen its contribution to the HIV response.

2020 - 2023 STRATEGIC FRAMEWORK



Values

The ILF is a results-orientated partnership underpinned by the values of collaboration, openness and transparency.


Foundation

The work of the ILF, an equal and inclusive multi-stakeholder partnership, is driven by an unrelenting focus on quality and reputation towards advancing the HIV response.

STRATEGIC PILLAR 1

GOAL

The ILF will continue to act as a cross-stakeholder, neutral, 'safe-space' platform that **actively expands and engages its membership base** in order to foster connections, dialogue and action.



Engage &
Grow
Membership

STRATEGIC PILLAR 1

OUTPUTS

- 1. Increased membership engagement** through an established calendar of up to six annual in-person convenings* and teleconferences that are well-planned, relevant, goal-oriented and participative.
- 2. Strategic membership growth** in alignment with the ILF Mission.
- 3. Membership of the ILF expanded** to enable members to participate in both the IAS cure and vaccine sub-advisory groups.



Engage &
Grow
Membership

GOAL



Advance
Priorities

The ILF members will **agree and advance specific topics** that address barriers along the HIV prevention, diagnosis and care continuum.

OUTPUTS

Advance Priorities

1. An agreed and clearly defined, collaborative and transparent **topic selection process.**
2. Annual **collaboration by the ILF** on:
 - One cross-cutting topic; and
 - One topic specific to an ILF industry*

Each topic must have a fixed timeline, to include a clear exit strategy, and pre-established metrics for success.

* ILF industries include pharmaceuticals (discovery), pharmaceuticals (generic), diagnostics.



The ILF will **develop and publish perspectives, where relevant**, to advance the global HIV response.




1. Documented broadly-agreed **perspectives or recommendations** on each topic.
2. Relevant perspectives/recommendations **shared publicly** via appropriate channels.

STRATEGY IMPLEMENTATION

*...refresh &
re-energize
the ILF*



WHAT DOES SUCCESS LOOK LIKE?



A committed, engaged and expanded membership base...

working together in a safe, neutral space to advance shared topics in HIV prevention, diagnosis and cure...

in order to advance the global HIV response through ongoing awareness raising and the publication of agreed perspectives.




“The ILF's capacity to bring various stakeholders around the table for open discussion - this is unique.” – ILF member



The **ILF STRATEGIC PLAN 2020 - 2023** was developed through a consultative process led by independent consultants. Inputs included a review of historic ILF documents; structured interviews with a broadly-representative cross-section of ILF members (industry and non-industry), past Co-Chairs, the IAS President; and discussions with IAS senior management.

APPENDIX 1

Evolution of ILF Industry Members



APPENDIX 2

Evolution of ILF Topics

Topic	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019
Post-trial care	M	MMR																
PrEP research and implementation				M	M	MM				M							R	
Research priorities for women and children							M	M	R		M							
- HIV prevention options for women												MMR			R			
- PMTCT									R	M	M	M						
- Paediatric ARVs (incl. GAP-f)								M	R	M	M	M	M	M	MMB	B	RRR	
Regulatory affairs															M	R	R	
Diagnostics													M	M	M		M	
Key populations														M				
GIPA															S	R		
Co-infections													M	M	R			
Pharmacovigilance																		
HIV cure																		
HIV vaccines																		
ILF scope												MM	MM					

LEGEND:	Topics planned in:		Topics addressed in:	
	3-year ILF strategic plan		R: Report	B: Webinar
	ILF annual workplan only		M: Meeting	S: Survey